We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FFR-Guided PCI Outperforms Drug Therapy Over Two Years in FAME 2 Trial

FFR-Guided PCI Outperforms Drug Therapy Over Two Years in FAME 2 Trial

September 2, 2014

Patients with stable coronary artery disease who were treated with medicines plus fractional flow reserve-guided percutaneous coronary intervention, or FFR-guided PCI, had fewer deaths, heart attacks and urgent revascularizations than patients treated with drugs alone, according to two-year data from St. Jude Medical’s FAME 2 clinical trial.

The randomized FAME 2 study, which launched in May 2010, examined the use of St. Jude's PressureWire Aeris and PressureWire Certus intravascular pressure sensors. The medical therapy consisted of daily aspirin, a beta blocker used alone or in combination with a calcium channel blocker and/or long-acting nitrate, and blood pressure medication.

Over the two years, patients in the PCI group had an 8.1 percent rate of death, heart attack or urgent revascularization, compared with 19.5 percent of patients on drug therapy alone, St. Jude reports. The biggest difference was seen in urgent revascularization — 4 percent in PCI patients versus 16.3 percent in the control group.

FFR identifies which coronary narrowings are responsible for obstructing blood flow to the heart and helps to determine which of those warrant stenting.

According to the St. Paul, Minn., devicemaker, more than 1,200 patients enrolled in 28 centers across the U.S., Canada and Europe before the study was halted in January 2012 due to strong positive results. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Commercial Operations

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing